Segment	Position ^a	AIV residues	H3N2 CIV residues	H3N8 CIV residues	Function ^c
PB2	76	T(96.5)	M(93.6)/I(17.4)	T(100)	Within PB1 and NP- binding domain (1)
	147	l(78)	T(100)	V(100)	Within NP-binding domain (1)
	365	M(97)	l(100)	M(100)	Within cap binding domain (2)
	570	M(94)	V(100)	M(100)	Within PB1 and NP- binding domain (1)
PB1	108	L(96)	l(100)	L(100)	Within RNA binding domain (3)
	361	S(94)	N(100)	S(100)	Virulence marker (4)
	377	D(97)	N(78.3)/D(21.7)	D(100)	Within RNA binding domain (3)
	517	I(96)	V(95.64)/I(4.34)	I(100)	Host range (5)
	723	R(97)	Q(93.6)/R(17.4)	R(100)	N/A
	744	M(94)	V(100)	M(100)	N/A
PA	65	S(93)	Y(100)	S(100)	Host adaptation (6)
	208	T(93)	A(100)	T(100)	Within translocation domain(7)
	234	D(98)	N(83.3)/D(16.7)	D(100)d	Within translocation domain(7)
	347	D(99)	N(29.2)/D(70.8)	D(100)	N/A
	369	A(96)	V(100)	A(100)	N/A
	441	M(93)	K(87.5)/R(12.5)	M(95.1)/I(4.9)	N/A
	615	K(94)	R(100)	K(100)	Polymerase activity and adaptation (8)
НА	10	T(95)	A(100)	T(100)	N/A
	81	D(74)	N(100)	Y(98.75)/H(1.25)	Glycosylation sequon (9)
	111	L(96)	I(83.3)/V(16.7)*	I(100)	N/A
	172	D(95)	N(100)	E(8.75)/K(91.25)	N/A
	222	W(90)	L(100)*	L(100)	Receptor binding (10, 11)
	435	H(96)	N(91.7)/H(4.15)/K(4.15)	H(100)	N/A
	489	D(92)	N(100)	Y(100)	N/A
NP	52	Y(58)	H(95.8)/Y(4.2)*	H(69.8)/Y(30.2)	N/A
	109	l(97)	l(62.5)/V(37.5)	I(100)	Host range (12)
	125	N(95)	G(91.7)/N(8.4)	N(100)	N/A
	159	M(95)	L(91.7)/M(8.4)	M(100)	N/A
	373	T(50)	K(95.8)/T(4.2)	T(100)	Putative NLS (13)
	428	A(94)	T(95.8)/A(4.2)	A(100)	N/A
	452	R(79)	K(95.8)/R(4.2)*	K(100)	N/A
	473	N(93)	K(95.8)/N(4.2)	N(100)	N/A
NA	24	M(95)	L(100)	N/A	N/A
	48	N(80)	S(91.7)/N(8.3)	N/A	N/A
	54	E(89)	K(100)	N/A	N/A
	81	P(74)	S(100)	N/A	N/A
	143	D(62)	N(100)	N/A	N/A
	156	P(96)	S(100)	N/A	N/A
	372	S(95)	L(100)	N/A	Sialidase activity (14)
	432	R(96)	G(100)	N/A	N/A
NS1	60	A(87)	l(100)	A(99.46)/T(0.54)	Within RNA-binding domain (15)
	67	R(91)	W(100)	Q(100)	Within RNA-binding domain (15)
	75	E(85)	K(100)	E(100)	Within effector domain (15)
	152	E(67)	N(100)	E(99.46)/D(0.54)	Within effector domain (15)
	172	E(95)	K(100)	E(100)	CPSF30 binding (15)

Table 1. Amino acid changes that differentiate H3N2 CIV from AIVs. Fixed mutations are shown in bold. Asterisks indicate convergent mutations between H3N2 and H3N8 CIVs. ^a Codon position. H3 numbering is used for codon positions in HA. ^b Amino acid present at the consensus level. The prevalence of each amino acid is shown in brackets. ^c Putative function of the amino acid residue or domain in which is located.

- 1. **Poole E, Elton D, Medcalf L, Digard P.** 2004. Functional domains of the influenza A virus PB2 protein: identification of NP- and PB1-binding sites. Virology **321**:120-133.
- 2. Guilligay D, Tarendeau F, Resa-Infante P, Coloma R, Crepin T, Sehr P, Lewis J, Ruigrok RW, Ortin J, Hart DJ, Cusack S. 2008. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nature structural & molecular biology **15**:500-506.
- 3. **Gonzalez S, Ortin J.** 1999. Distinct regions of influenza virus PB1 polymerase subunit recognize vRNA and cRNA templates. The EMBO journal **18**:3767-3775.
- 4. **Allen JE, Gardner SN, Vitalis EA, Slezak TR.** 2009. Conserved amino acid markers from past influenza pandemic strains. BMC microbiology **9:**77.
- 5. **Tamuri AU, Dos Reis M, Hay AJ, Goldstein RA.** 2009. Identifying changes in selective constraints: host shifts in influenza. PLoS computational biology **5**:e1000564.
- 6. **Miotto O, Heiny AT, Albrecht R, Garcia-Sastre A, Tan TW, August JT, Brusic V.** 2010. Complete-proteome mapping of human influenza A adaptive mutations: implications for human transmissibility of zoonotic strains. PloS one **5:**e9025.
- Nieto A, de la Luna S, Barcena J, Portela A, Ortin J. 1994. Complex structure of the nuclear translocation signal of influenza virus polymerase PA subunit. The Journal of general virology 75 (Pt 1):29-36.
- 8. **Gabriel G, Dauber B, Wolff T, Planz O, Klenk HD, Stech J.** 2005. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. Proceedings of the National Academy of Sciences of the United States of America **102**:18590-18595.
- 9. **Zhang M, Gaschen B, Blay W, Foley B, Haigwood N, Kuiken C, Korber B.** 2004. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology **14:**1229-1246.
- Collins PJ, Vachieri SG, Haire LF, Ogrodowicz RW, Martin SR, Walker PA, Xiong X, Gamblin SJ, Skehel JJ. 2014. Recent evolution of equine influenza and the origin of canine influenza. Proceedings of the National Academy of Sciences of the United States of America 111:11175-11180.
- Yang G, Li S, Blackmon S, Ye J, Bradley KC, Cooley J, Smith D, Hanson L, Cardona C, Steinhauer DA, Webby R, Liao M, Wan XF. 2013. Mutation tryptophan to leucine at position 222 of haemagglutinin could facilitate H3N2 influenza A virus infection in dogs. The Journal of general virology 94:2599-2608.
- 12. Chen GW, Chang SC, Mok CK, Lo YL, Kung YN, Huang JH, Shih YH, Wang JY, Chiang C, Chen CJ, Shih SR. 2006. Genomic

signatures of human versus avian influenza A viruses. Emerging infectious diseases **12:**1353-1360.

- 13. **Hutchinson EC, Fodor E.** 2012. Nuclear import of the influenza A virus transcriptional machinery. Vaccine **30**:7353-7358.
- 14. Kobasa D, Kodihalli S, Luo M, Castrucci MR, Donatelli I, Suzuki Y, Suzuki T, Kawaoka Y. 1999. Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase. Journal of virology **73**:6743-6751.
- 15. **Hale BG, Randall RE, Ortin J, Jackson D.** 2008. The multifunctional NS1 protein of influenza A viruses. The Journal of general virology **89**:2359-2376.